Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05399745

BILACO Trial: Biliary Atresia - a Severe Complex Congenital Liver Disease

Biliary atresia is the most severe form of cholestatic liver disease. The children have high morbidity and mortality and get devastating pruritus and fatigue, failure to thrive, progressive hepatic failure and impaired neurodevelopment. The etiology is mostly unknown. More than half need a new liver from a living or deceased donor during childhood. However, correct timing of the transplantation is extremely difficult because of lack of consensus based on clinical assessment tools. All though the incidence is low, the cost of this disease is tremendous from both a clinical and human perspective. So far, protocolized neurodevelopment tests, genetic profiling, precise malnutrition evaluation based on clinical appearance, biochemical markers and brain MRI-scans, body composition, immunological function, level of physical activity and optimal time of transplantation in cholestatic children are unknown.

The aim is to determine risk factors for neurocognitive impairment in children suffering from severe cholestasis in order to determine optimal time for liver transplantation from a brain perspective.

In a prospective study, the investigators will investigate risk factors related to brain-, heart-, gut- and immunological function in the Danish cohort. This cohort consists of 75 children aged 0-18 years. In addition, 30 aged and gender matched healthy and 20 tetra fallot children will serve as control groups. The children will undergo extensive and advanced liver function evaluation, genetic profiling, nutrition and immunological status, neuro-imaging and neurocognitive evaluation at time of diagnose, 2 years of age, pre-school, pre-teenage, and teenage. In case of a liver transplantation, additional neuro-cognitive tests will be performed

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Biliary Atresia Bile Duct Diseases Biliary Tract Diseases Cognition Disorders Cognitive Dysfunction Cognitive Impairment Congenital Abnormalities Congenital, Hereditary, and Neonatal Diseases and Abnormalities Digestive System Abnormalities Digestive System Diseases Mental Disorders Neurocognitive Disorders

Age range

0 year–18 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Rigshospitalet

Copenhagen, 2100, Denmark

Location status: Recruiting

Location contact

Vibeke Brix Christensen, MD, PhD, DMSc

CONTACT

[email protected]

+4535458842

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Biliary atresia
  • Tetralogy of Fallot
  • Healthy controls

Exclusion criteria

  • Not able to participate in exams

Treatment and study plan

Neurocognitive monitoring

Other

Neurocognitive tests and MRI of the brain

Primary outcomes

  1. MRI of the brain

    Time frame: Inclusion

    % of patients with anatomic anomalies on MRI of the brain

  2. Neurocognitive status: Early movement repertoire (General movement)

    Time frame: Inclusion

    Neurocognitive test panel depending on age at inclusion

    % of patients with of abnormal movement assessed using early movement repertoire (GM) if inclusion at diagnosis. Early movement repertoire is a measurement tool where abnormal movement is identified.

  3. Neurocognitive status: Alberta Infant Motor Scale

    Time frame: Inclusion

    Neurocognitive test panel depending on age at inclusion:

    Alberta Infant Motor Scale if inclusion at diagnosis

    Percentile, highest is the best

  4. Neurocognitive status: Bayley Scales of Development III

    Time frame: Inclusion

    Neurocognitive test panel depending on age at inclusion:

    Bayley Scales of Development III if inclusion up to 2.5 years:

    From 0-200, highest is best

  5. Neurocognitive status: WIPPSI

    Time frame: Inclusion

    Neurocognitive test panel depending on age at inclusion:

    WIPPSI if inclusion between 2.5-6 years:

    Wechsler Preschool and Primary Scale of Intelligence, from 41 to 160, highest is best

  6. Neurocognitive status: ABC Movement

    Time frame: Inclusion

    Neurocognitive test panel depending on age at inclusion:

    ABC Movement if inclusion between 2.5-16 years

    Movement Assessment Battery for Children, mean 10 SD 3, highest is best

  7. Neurocognitive status: WISC-IV

    Time frame: Inclusion

    Neurocognitive test panel depending on age at inclusion:

    WISC-IV if inclusion between 6-16 years

    Wechsler Intelligence Scale for Children, 40 to 160, highest is best

  8. Neurocognitive status: Auditory Verbal Learning Test/ToMaL

    Time frame: Inclusion

    Neurocognitive test panel depending on age at inclusion:

    Auditory Verbal Learning Test/ToMaL if inclusion between 6-18 years Mean 10 SD 3, highest is best

  9. Neurocognitive status: TEA-Ch

    Time frame: Inclusion

    Neurocognitive test panel depending on age at inclusion:

    TEA-Ch if inclusion between 6-18 years

    Test of Everyday Attention for Children, normalized to z-score, highest is best

  10. Neurocognitive status: BADS-C

    Time frame: Inclusion

    Neurocognitive test panel depending on age at inclusion:

    BADS-C if inclusion between 6-18 years Behavioural Assessment of the Dysexecutive Syndrome in Children, 0-24, mean 10 SD 3, highest is best

  11. Neurocognitive status: Test of Visual Perceptual Skills

    Time frame: Inclusion

    Neurocognitive test panel depending on age at inclusion:

    Test of Visual Perceptual Skills if inclusion between 6-18 years

    Percentile, highest is best

  12. Neurocognitive status: CANTAB

    Time frame: Inclusion

    Neurocognitive test panel depending on age at inclusion:

    CANTAB if inclusion between 6-18 years Cambridge Neuropsychological Test Automated Battery

  13. Neurocognitive status: The Beery Visuo-Motor Integration test

    Time frame: Inclusion

    Neurocognitive test panel depending on age at inclusion:

    The Beery Visuo-Motor Integration test if inclusion between 6-18 years Mean of 100 and standard deviation of 15, highest is best

  14. Neurocognitive status: WAIS IV

    Time frame: Inclusion

    Neurocognitive test panel depending on age at inclusion:

    WAIS IV if inclusion from 16 to 18 years Wechsler Adult Intelligence Scale, 40-160, highest is best

  15. Neurocognitive status: Kiddie-sads

    Time frame: Inclusion

    Neurocognitive test panel depending on age at inclusion:

    Kiddie-sads if included between 2-18 years Kiddie Schedule for Affective Disorders and Schizophrenia, 0-61, lowest is best

  16. Neurocognitive status: BRIEF 1

    Time frame: Inclusion

    Neurocognitive test panel depending on age at inclusion:

    BRIEF 1 if inclusion up to 6 years Behaviour Rating Inventory of Executive Function, percentile, lowest is best

  17. Neurocognitive status: BRIEF 2

    Time frame: Inclusion

    Neurocognitive test panel depending on age at inclusion:

    BRIEF 2 if inclusion between 6-18 years Behaviour Rating Inventory of Executive Function, percentile, lowest is best

  18. Neurocognitive status: CBCL

    Time frame: Inclusion

    Neurocognitive test panel depending on age at inclusion:

    CBCL if included between 2-18 years Child Behavior Checklist, percentile, lowest is best

  19. Neurocognitive status: ADHD screening

    Time frame: Inclusion

    Neurocognitive test panel depending on age at inclusion:

    ADHD screening if included between 2-18 years Lowest is best, 0-78

  20. Neurocognitive status: SRS-2

    Time frame: Inclusion

    Neurocognitive test panel depending on age at inclusion:

    SRS-2 screening if included between 6-18 years

    Social Responsiveness Scale, 32-114. lowest is best

  21. Neurocognitive status: Vineland

    Time frame: Inclusion

    Neurocognitive test panel depending on age at inclusion:

    Vineland screening if included between 6-18 years Vineland Adaptive Behavior Scales, 20 to 160, highest is best

  22. MRI of the brain

    Time frame: 1 year

    % of patients with anatomic anomalies on MRI of the brain

  23. Neurocognitive status: Alberta Infant Motor Scale

    Time frame: 1 year

    Alberta Infant Motor Scale Percentile, highest is the best

  24. Neurocognitive status: Bayley Scales of Development III

    Time frame: 1 year

    Bayley Scales of Development III

    From 0-200, highest is best

  25. Neurocognitive status: BRIEF 1

    Time frame: 1 year

    BRIEF 1 Behaviour Rating Inventory of Executive Function, percentile, lowest is best

  26. Neurocognitive status: CBCL

    Time frame: 1 year

    CBCL Child Behavior Checklist, percentile, lowest is best

  27. Neurocognitive status: Kiddie-Sads

    Time frame: 1 year

    Kiddie-Sads Kiddie Schedule for Affective Disorders and Schizophrenia, 0-61, lowest is best

  28. MRI of the brain

    Time frame: 2 years

    % of patients with anatomic anomalies on MRI of the brain

  29. Neurocognitive status: Bayley Scales of Development III

    Time frame: 2 years

    Bayley Scales of Development III From 0-200, highest is best

  30. Neurocognitive status: BRIEF 1

    Time frame: 2 years

    BRIEF 1 Behaviour Rating Inventory of Executive Function, percentile, lowest is best

  31. Neurocognitive status: CBCL

    Time frame: 2 years

    CBCL Child Behavior Checklist, percentile, lowest is best

  32. Neurocognitive status: Kiddie-Sads

    Time frame: 2 years

    Kiddie-Sads Kiddie Schedule for Affective Disorders and Schizophrenia, 0-61, lowest is best

  33. Neurocognitive status: ADHD

    Time frame: 2 years

    ADHD Lowest is best, 0-78

  34. Neurocognitive status: Vineland

    Time frame: 2 years

    Vineland Adaptive Behavior Scales, 20 to 160, highest is best

  35. MRI of the brain

    Time frame: 6 years

    % of patients with anatomic anomalies on MRI of the brain

  36. Neurocognitive: Movement ABC

    Time frame: 6 years

    Neurocognitive test panel depending on age Movement Assessment Battery for Children, mean 10 SD 3, highest is best

  37. Neurocognitive status: WISC-IV

    Time frame: 6 years

    WISC-IV

    Wechsler Intelligence Scale for Children, 40 to 160, highest is best

  38. Neurocognitive status: Auditory Verbal Learning Test/ToMaL

    Time frame: 6 years

    Auditory Verbal Learning Test/ToMaL Mean 10 SD 3, highest is best

  39. Neurocognitive status: TEA-Ch

    Time frame: 6 years

    TEA-Ch Test of Everyday Attention for Children, normalized to z-score, highest is best

  40. Neurocognitive status: BADS-C

    Time frame: 6 years

    BADS-C Behavioural Assessment of the Dysexecutive Syndrome in Children, 0-24, mean 10 SD 3, highest is best

  41. Neurocognitive status: Test of Visual Perceptual Skills

    Time frame: 6 years

    Test of Visual Perceptual Skills Percentile, highest is best

  42. Neurocognitive status: The Beery Visuo-Motor Integration test

    Time frame: 6 years

    The Beery Visuo-Motor Integration test Mean of 100 and standard deviation of 15, highest is best

  43. Neurocognitive status: CANTAB

    Time frame: 6 years

    CANTAB Cambridge Neuropsychological Test Automated Battery

  44. Neurocognitive status: BRIEF 2

    Time frame: 6 years

    BRIEF 2 Behaviour Rating Inventory of Executive Function, percentile, lowest is best

  45. Neurocognitive status: ADHD screening

    Time frame: 6 years

    ADHD screening Lowest is best, 0-78

  46. Neurocognitive status: SRS-2

    Time frame: 6 years

    SRS-2 Social Responsiveness Scale, 32-114. lowest is best

  47. Neurocognitive status: Kiddie-Sads

    Time frame: 6 years

    Kiddie-Sads Kiddie Schedule for Affective Disorders and Schizophrenia, 0-61, lowest is best

  48. Neurocognitive status: CBCL

    Time frame: 6 years

    CBCL Child Behavior Checklist, percentile, lowest is best

  49. Neurocognitive status: Vineland

    Time frame: 6 years

    Vineland Vineland Adaptive Behavior Scales, 20 to 160, highest is best

  50. MRI of the brain

    Time frame: 11 years

    % of patients with anatomic anomalies on MRI of the brain

  51. Neurocognitive status: Movement ABC

    Time frame: 11 years

    Neurocognitive test panel depending on age at inclusion:

    ABC Movement if inclusion between 2.5-16 years

    Movement Assessment Battery for Children, mean 10 SD 3, highest is best

  52. Neurocognitive status: WISC-IV

    Time frame: 11 years

    WISC-IV

    Wechsler Intelligence Scale for Children, 40 to 160, highest is best

  53. Neurocognitive status: Auditory Verbal Learning Test/ToMaL

    Time frame: 11 years

    Auditory Verbal Learning Test/ToMaL Mean 10 SD 3, highest is best

  54. Neurocognitive status:TEA-Ch

    Time frame: 11 years

    TEA-Ch Test of Everyday Attention for Children, normalized to z-score, highest is best

  55. Neurocognitive status: BADS-C

    Time frame: 11 years

    BADS-C Behavioural Assessment of the Dysexecutive Syndrome in Children, 0-24, mean 10 SD 3, highest is best

  56. Neurocognitive status: Test of Visual Perceptual Skills

    Time frame: 11 years

    Test of Visual Perceptual Skills Percentile, highest is best

  57. Neurocognitive status: The Beery Visuo-Motor Integration test

    Time frame: 11 years

    The Beery Visuo-Motor Integration test Mean of 100 and standard deviation of 15, highest is best

  58. Neurocognitive status: CANTAB

    Time frame: 11 years

    CANTAB Cambridge Neuropsychological Test Automated Battery

  59. Neurocognitive status: BRIEF 2

    Time frame: 11 years

    BRIEF 2 Behaviour Rating Inventory of Executive Function, percentile, lowest is best

  60. Neurocognitive status: ADHD screening

    Time frame: 11 years

    ADHD screening Lowest is best, 0-78

  61. Neurocognitive status: SRS-2

    Time frame: 11 years

    SRS-2 Social Responsiveness Scale, 32-114. lowest is best

  62. Neurocognitive status: Kiddie-Sads

    Time frame: 11 years

    Kiddie-Sads Kiddie Schedule for Affective Disorders and Schizophrenia, 0-61, lowest is best

  63. Neurocognitive status: CBCL

    Time frame: 11 years

    CBCL Child Behavior Checklist, percentile, lowest is best

  64. Neurocognitive status: Vineland

    Time frame: 11 years

    Vineland Adaptive Behavior Scales, 20 to 160, highest is best

  65. MRI of the brain

    Time frame: 16 years

    % of patients with anatomic anomalies on MRI of the brain

  66. Neurocognitive status: Movement ABC

    Time frame: 16 years

    Neurocognitive test panel depending on age at inclusion:

    ABC Movement if inclusion between 2.5-16 years

    Movement Assessment Battery for Children, mean 10 SD 3, highest is best

  67. Neurocognitive status: WISC-IV

    Time frame: 16 years

    WISC-IV Wechsler Adult Intelligence Scale, 40-160, highest is best

  68. Neurocognitive status: Auditory Verbal Learning Test/ToMaL

    Time frame: 16 years

    Auditory Verbal Learning Test/ToMaL Mean 10 SD 3, highest is best

  69. Neurocognitive status: TEA-Ch

    Time frame: 16 years

    TEA-Ch Test of Everyday Attention for Children, normalized to z-score, highest is best

  70. Neurocognitive status: BADS-C

    Time frame: 16 years

    BADS-C Behavioural Assessment of the Dysexecutive Syndrome in Children, 0-24, mean 10 SD 3, highest is best

  71. Neurocognitive status: Test of Visual Perceptual Skills

    Time frame: 16 years

    Test of Visual Perceptual Skills Percentile, highest is best

  72. Neurocognitive status: The Beery Visuo-Motor Integration test

    Time frame: 16 years

    The Beery Visuo-Motor Integration test Mean of 100 and standard deviation of 15, highest is best

  73. Neurocognitive status: CANTAB

    Time frame: 16 years

    CANTAB Cambridge Neuropsychological Test Automated Battery

  74. Neurocognitive status: BRIEF 2

    Time frame: 16 years

    BRIEF 2 Behaviour Rating Inventory of Executive Function, percentile, lowest is best

  75. Neurocognitive status: ADHD screening

    Time frame: 16 years

    ADHD screening Lowest is best, 0-78

  76. Neurocognitive status: SRS-2

    Time frame: 16 years

    SRS-2 Social Responsiveness Scale, 32-114. lowest is best

  77. Neurocognitive status: Kiddie-Sads

    Time frame: 16 years

    Kiddie-Sads Kiddie Schedule for Affective Disorders and Schizophrenia, 0-61, lowest is best

  78. Neurocognitive status: CBCL

    Time frame: 16 years

    CBCL Child Behavior Checklist, percentile, lowest is best

  79. Neurocognitive status: Vineland

    Time frame: 16 years

    Vineland Adaptive Behavior Scales, 20 to 160, highest is best

Secondary outcomes

  1. Genetics: Whole genome sequencing of blood

    Time frame: Inclusion

    Whole genome sequencing of blood

  2. Genetics: Whole genome sequencing of liver biopsy

    Time frame: Inclusion

    Whole genome sequencing of liver biopsy

  3. Microbiome: Urine proteomics

    Time frame: Inclusion

    Microbiome measurements on urine

  4. Microbiome: Feces proteomics

    Time frame: Inclusion

    Microbiome measurements on feces

  5. Microbiome: Saliva proteomics

    Time frame: Inclusion

    Microbiome measurements on saliva

  6. Microbiome: Feces Next Generation Sequencing of microbial DNA

    Time frame: Inclusion

    Microbiome measurement on feces

  7. Microbiome: Urine Next Generation Sequencing of microbial DNA

    Time frame: Inclusion

    Microbiome measurement on urine

  8. Microbiome: Saliva Next Generation Sequencing of microbial DNA

    Time frame: Inclusion

    Microbiome measurement on saliva

  9. Microbiome: Feces metabolomics

    Time frame: Inclusion

    Microbiome measurements on feces

  10. Microbiome: Urine metabolomics

    Time frame: Inclusion

    Microbiome measurements on urine

  11. Microbiome: Saliva metabolomics

    Time frame: Inclusion

    Microbiome measurements on saliva

  12. Microbiome: Feces metatranscriptomics

    Time frame: Inclusion

    Microbiome measurements on feces

  13. Microbiome: Urine metatranscriptomics

    Time frame: Inclusion

    Microbiome measurements on urine

  14. Microbiome: Saliva metatranscriptomics

    Time frame: Inclusion

    Microbiome measurements on saliva

  15. Genetics: Whole genome sequencing of blood

    Time frame: 1 year

    Whole genome sequencing of blood

  16. Genetics: Whole genome sequencing of liver biopsy

    Time frame: 1 year

    Whole genome sequencing of liver biopsy

  17. Microbiome: Feces metatranscriptomics

    Time frame: 1 year

    Microbiome measurements on feces

  18. Microbiome: Urine metatranscriptomics

    Time frame: 1 year

    Microbiome measurements on urine

  19. Microbiome: Saliva metatranscriptomics

    Time frame: 1 year

    Microbiome measurements on saliva

  20. Microbiome: Urine Next Generation Sequencing of microbial DNA

    Time frame: 1 year

    Microbiome measurements on urine

  21. Microbiome: Feces Next Generation Sequencing of microbial DNA

    Time frame: 1 year

    Microbiome measurements on feces

  22. Microbiome: Saliva Next Generation Sequencing of microbial DNA

    Time frame: 1 year

    Microbiome measurements on saliva

  23. Microbiome: Saliva metabolomics

    Time frame: 1 year

    Microbiome measurements on saliva

  24. Microbiome: Urine metabolomics

    Time frame: 1 year

    Microbiome measurements on urine

  25. Microbiome: Feces metabolomics

    Time frame: 1 year

    Microbiome measurements on feces

  26. Microbiome: Saliva proteomics

    Time frame: 1 year

    Microbiome measurements on saliva

  27. Microbiome: Urine proteomics

    Time frame: 1 year

    Microbiome measurements on urine

  28. Microbiome: Feces proteomics

    Time frame: 1 year

    Microbiome measurements on feces

  29. Genetics: Whole genome sequencing of blood

    Time frame: 2 years

    Whole genome sequencing of blood

  30. Genetics: Whole genome sequencing of liver biopsy

    Time frame: 2 years

    Whole genome sequencing of liver biopsy

  31. Microbiome: Feces metatranscriptomics

    Time frame: 2 years

    Microbiome measurements on feces

  32. Microbiome: Urine metatranscriptomics

    Time frame: 2 years

    Microbiome measurements on urine

  33. Microbiome: Saliva metatranscriptomics

    Time frame: 2 years

    Microbiome measurements on saliva

  34. Microbiome: Saliva metabolomics

    Time frame: 2 years

    Microbiome measurements on saliva

  35. Microbiome: Feces metabolomics

    Time frame: 2 years

    Microbiome measurements on feces

  36. Microbiome: Urine metabolomics

    Time frame: 2 years

    Microbiome measurements on urine

  37. Microbiome: Urine proteomics

    Time frame: 2 years

    Microbiome measurements on urine

  38. Microbiome: Feces proteomics

    Time frame: 2 years

    Microbiome measurements on feces

  39. Microbiome: Saliva proteomics

    Time frame: 2 years

    Microbiome measurements on saliva

  40. Microbiome: Urine Next Generation Sequencing of microbial DNA

    Time frame: 2 years

    Microbiome measurements on urine

  41. Microbiome: Saliva Next Generation Sequencing of microbial DNA

    Time frame: 2 years

    Microbiome measurements on saliva

  42. Microbiome: Feces Next Generation Sequencing of microbial DNA

    Time frame: 2 years

    Microbiome measurements on feces

  43. Genetics: Whole genome sequencing of blood

    Time frame: 6 years

    Whole genome sequencing of blood

  44. Genetics: Whole genome sequencing of liver biopsy

    Time frame: 6 years

    Whole genome sequencing of liver biopsy

  45. Microbiome: Feces Next Generation Sequencing of microbial DNA

    Time frame: 6 years

    Microbiome measurements on feces

  46. Microbiome: Feces metatranscriptomics

    Time frame: 6 years

    Microbiome measurements on feces

  47. Microbiome: Feces metabolomics

    Time frame: 6 years

    Microbiome measurements on feces

  48. Microbiome: Feces proteomics

    Time frame: 6 years

    Microbiome measurements on feces

  49. Microbiome: Urine Next Generation Sequencing of microbial DNA

    Time frame: 6 years

    Microbiome measurements on urine

  50. Microbiome: Urine metatranscriptomics

    Time frame: 6 years

    Microbiome measurements on urine

  51. Microbiome: Urine metabolomics

    Time frame: 6 years

    Microbiome measurements on urine

  52. Microbiome: Urine proteomics

    Time frame: 6 years

    Microbiome measurements on urine

  53. Microbiome: Saliva Next Generation Sequencing of microbial DNA

    Time frame: 6 years

    Microbiome measurements on saliva

  54. Microbiome: Saliva metatranscriptomics

    Time frame: 6 years

    Microbiome measurements on saliva

  55. Microbiome: Saliva metabolomics

    Time frame: 6 years

    Microbiome measurements on saliva

  56. Microbiome: Saliva proteomics

    Time frame: 6 years

    Microbiome measurements on saliva

  57. Genetics: Whole genome sequencing of blood

    Time frame: 11 years

    Whole genome sequencing of blood

  58. Genetics: Whole genome sequencing of liver biopsy

    Time frame: 11 years

    Whole genome sequencing of liver biopsy

  59. Microbiome: Feces Next Generation Sequencing of microbial DNA

    Time frame: 11 years

    Microbiome measurements on feces

  60. Microbiome: Feces metatranscriptomics

    Time frame: 11 years

    Microbiome measurements on feces

  61. Microbiome: Feces metabolomics

    Time frame: 11 years

    Microbiome measurements on feces

  62. Microbiome: Feces proteomics

    Time frame: 11 years

    Microbiome measurements on feces

  63. Microbiome: Urine Next Generation Sequencing of microbial DNA

    Time frame: 11 years

    Microbiome measurements on urine

  64. Microbiome: Urine metatranscriptomics

    Time frame: 11 years

    Microbiome measurements on urine

  65. Microbiome: Urine metabolomics

    Time frame: 11 years

    Microbiome measurements on urine

  66. Microbiome: Urine proteomics

    Time frame: 11 years

    Microbiome measurements on urine

  67. Microbiome: Saliva Next Generation Sequencing of microbial DNA

    Time frame: 11 years

    Microbiome measurements on saliva

  68. Microbiome: Saliva metatranscriptomics

    Time frame: 11 years

    Microbiome measurements on saliva

  69. Microbiome: Saliva metabolomics

    Time frame: 11 years

    Microbiome measurements on saliva

  70. Microbiome: Saliva proteomics

    Time frame: 11 years

    Microbiome measurements on saliva

  71. Genetics: Whole genome sequencing of blood

    Time frame: 16 years

    Whole genome sequencing of blood

  72. Genetics: Whole genome sequencing of liver biopsy

    Time frame: 16 years

    Whole genome sequencing of liver biopsy

  73. Microbiome: Feces metatranscriptomics

    Time frame: 16 years

    Microbiome measurements on feces

  74. Microbiome: Feces Next Generation Sequencing of microbial DNA

    Time frame: 16 years

    Microbiome measurements on feces

  75. Microbiome: Feces metabolomics

    Time frame: 16 years

    Microbiome measurements on feces

  76. Microbiome: Feces proteomics

    Time frame: 16 years

    Microbiome measurements on feces

  77. Microbiome: Urine metatranscriptomics

    Time frame: 16 years

    Microbiome measurements on urine

  78. Microbiome: Urine Next Generation Sequencing of microbial DNA

    Time frame: 16 years

    Microbiome measurements on urine

  79. Microbiome: Urine metabolomics

    Time frame: 16 years

    Microbiome measurements on urine

  80. Microbiome: Urine proteomics

    Time frame: 16 years

    Microbiome measurements on urine

  81. Microbiome: Saliva metatranscriptomics

    Time frame: 16 years

    Microbiome measurements on saliva

  82. Microbiome: Saliva Next Generation Sequencing of microbial DNA

    Time frame: 16 years

    Microbiome measurements on saliva

  83. Microbiome: Saliva metabolomics

    Time frame: 16 years

    Microbiome measurements on saliva

  84. Microbiome: Saliva proteomics

    Time frame: 16 years

    Microbiome measurements on saliva

  85. Status of the cardiac system: Ultrasound of the heart

    Time frame: Inclusion

    % of patients with anatomic anomalies on ultrasound of the heart

  86. Status of the cardiac system: MRI of the lymph system

    Time frame: Inclusion

    % of patients with central lymph system anomaly

  87. Status of the cardiac system: Near Infrared Fluorescence of the lymph system

    Time frame: Inclusion

    Near Infrared Fluorescence of the lymph system

  88. Status of the cardiac system: Ultrasound of the heart

    Time frame: 1 year

    % of patients with anatomic anomalies on ultrasound of the heart

  89. Status of the cardiac system: MRI of the lymph system

    Time frame: 1 year

    % of patients with central lymph system anomaly

  90. Status of the cardiac system: Near Infrared Fluorescence of the lymph system

    Time frame: 1 year

    Near Infrared Fluorescence of the lymph system

  91. Status of the cardiac system: Ultrasound of the heart

    Time frame: 2 years

    % of patients with anatomic anomalies on ultrasound of the heart

  92. Status of the cardiac system: MRI of the lymph system

    Time frame: 2 years

    % of patients with central lymph system anomaly

  93. Status of the cardiac system: Near Infrared Fluorescence of the lymph system

    Time frame: 2 years

    Near Infrared Fluorescence of the lymph system

  94. Status of the cardiac system: Ultrasound of the heart

    Time frame: 6 years

    % of patients with anatomic anomalies on ultrasound of the heart

  95. Status of the cardiac system: MRI of the lymph system

    Time frame: 6 years

    % of patients with central lymph system anomaly

  96. Status of the cardiac system: Near Infrared Fluorescence of the lymph system

    Time frame: 6 years

    Near Infrared Fluorescence of the lymph system

  97. Status of the cardiac system: Ultrasound of the heart

    Time frame: 11 years

    % of patients with anatomic anomalies on ultrasound of the heart

  98. Status of the cardiac system: MRI of the lymph system

    Time frame: 11 years

    % of patients with central lymph system anomaly

  99. Status of the cardiac system: Near Infrared Fluorescence of the lymph system

    Time frame: 11 years

    Near Infrared Fluorescence of the lymph system

  100. Status of the cardiac system: Ultrasound of the heart

    Time frame: 16 years

    % of patients with anatomic anomalies on ultrasound of the heart

  101. Status of the cardiac system: MRI of the lymph system

    Time frame: 16 years

    % of patients with central lymph system anomaly

  102. Status of the cardiac system: Near Infrared Fluorescence of the lymph system

    Time frame: 16 years

    Near Infrared Fluorescence of the lymph system

  103. Level of Physical activity

    Time frame: Inclusion

    Accelerometer measurements

  104. Level of Physical activity

    Time frame: 1 year

    Accelerometer measurements

  105. Level of Physical activity

    Time frame: 2 years

    Accelerometer measurements

  106. Level of Physical activity

    Time frame: 6 years

    Accelerometer measurements

  107. Level of Physical activity

    Time frame: 11 years

    Accelerometer measurements

  108. Level of Physical activity

    Time frame: 16 years

    Accelerometer measurements

  109. Ultrasound of liver and bile ducts with elastography

    Time frame: Inclusion

    % of patients with liver fibrosis measured with ultrasound

  110. Liver biopsy

    Time frame: Inclusion

    Level of liver fibrosis (grade 0-4)

  111. FGF-19; Fibroblast growth factor 19

    Time frame: Inclusion

    Liver fibrosis status

  112. ELF-score: Enhanced Liver Fibrosis

    Time frame: Inclusion

    Liver fibrosis status

  113. INR: international normalized ratio

    Time frame: Inclusion

    Standard liver evaluation

  114. prothrombin+proconvertin (PP)

    Time frame: Inclusion

    Standard liver evaluation

  115. ALAT: alanine transaminase

    Time frame: Inclusion

    Standard liver evaluation

  116. GGT: Gamma-glutamyl transferase

    Time frame: Inclusion

    Standard liver evaluation

  117. Bilirubin

    Time frame: Inclusion

    Standard liver evaluation

  118. ASAT: Aspartate transaminase

    Time frame: Inclusion

    Standard liver evaluation

  119. Alkaline phosphatase

    Time frame: Inclusion

    Standard liver evaluation

  120. Ammonia

    Time frame: Inclusion

    Standard liver evaluation

  121. Thrombocytes

    Time frame: Inclusion

    Standard liver evaluation

  122. Ultrasound of liver and bile ducts with elastography

    Time frame: 1 year

    % of patients with liver fibrosis measured with ultrasound

  123. FGF-19: Fibroblast growth factor 19

    Time frame: 1 year

    Liver fibrosis status

  124. ELF-score: Enhanced Liver Fibrosis

    Time frame: 1 year

    Liver fibrosis status

  125. INR: international normalized ratio

    Time frame: 1 year

    Standard liver evaluation

  126. prothrombin+proconvertin (PP)

    Time frame: 1 year

    Standard liver evaluation

  127. ALAT: alanine transaminase

    Time frame: 1 year

    Standard liver evaluation

  128. ASAT: Aspartate transaminase

    Time frame: 1 year

    Standard liver evaluation

  129. GGT: Gamma-glutamyl transferase

    Time frame: 1 year

    Standard liver evaluation

  130. Bilirubin

    Time frame: 1 year

    Standard liver evaluation

  131. Alkaline phosphatase

    Time frame: 1 year

    Standard liver evaluation

  132. Ammonia

    Time frame: 1 year

    Standard liver evaluation

  133. Thrombocytes

    Time frame: 1 year

    Standard liver evaluation

  134. Liver biopsy

    Time frame: 1 year

    Level of liver fibrosis (grade 0-4)

  135. Ultrasound of liver and bile ducts with elastography

    Time frame: 2 years

    % of patients with liver fibrosis measured with ultrasound

  136. FGF-19: Fibroblast growth factor 19

    Time frame: 2 years

    Liver fibrosis status

  137. ELF-score: Enhanced Liver Fibrosis

    Time frame: 2 years

    Liver fibrosis status

  138. Liver biopsy

    Time frame: 2 years

    Level of liver fibrosis (grade 0-4)

  139. INR: international normalized ratio

    Time frame: 2 years

    Standard liver evaluation

  140. prothrombin+proconvertin (PP)

    Time frame: 2 years

    Standard liver evaluation

  141. ALAT: alanine transaminase

    Time frame: 2 years

    Standard liver evaluation

  142. ASAT: Aspartate transaminase

    Time frame: 2 years

    Standard liver evaluation

  143. GGT: Gamma-glutamyl transferase

    Time frame: 2 years

    Standard liver evaluation

  144. Alkaline phosphatase

    Time frame: 2 years

    Standard liver evaluation

  145. Bilirubin

    Time frame: 2 years

    Standard liver evaluation

  146. Ammonia

    Time frame: 2 years

    Standard liver evaluation

  147. Thrombocytes

    Time frame: 2 years

    Standard liver evaluation

  148. Ultrasound of liver and bile ducts with elastography

    Time frame: 6 years

    % of patients with liver fibrosis measured with ultrasound

  149. Liver biopsy

    Time frame: 6 years

    Level of liver fibrosis (grade 0-4)

  150. ELF-score: Enhanced Liver Fibrosis

    Time frame: 6 years

    Liver fibrosis status

  151. FGF-19: Fibroblast growth factor 19

    Time frame: 6 years

    Liver fibrosis status

  152. INR: international normalized ratio

    Time frame: 6 years

    Standard liver evaluation

  153. prothrombin+proconvertin (PP)

    Time frame: 6 years

    Standard liver evaluation

  154. ALAT: alanine transaminase

    Time frame: 6 years

    Standard liver evaluation

  155. ASAT: Aspartate transaminase

    Time frame: 6 years

    Standard liver evaluation

  156. GGT: Gamma-glutamyl transferase

    Time frame: 6 years

    Standard liver evaluation

  157. Bilirubin

    Time frame: 6 years

    Standard liver evaluation

  158. Alkaline phosphatase

    Time frame: 6 years

    Standard liver evaluation

  159. Ammonia

    Time frame: 6 years

    Standard liver evaluation

  160. Thrombocytes

    Time frame: 6 years

    Standard liver evaluation

  161. Ultrasound of liver and bile ducts with elastography

    Time frame: 11 years

    % of patients with liver fibrosis measured with ultrasound

  162. Liver biopsy

    Time frame: 11 years

    Level of liver fibrosis (grade 0-4)

  163. FGF-19: Fibroblast growth factor 19

    Time frame: 11 years

    Liver fibrosis status

  164. ELF-score: Enhanced Liver Fibrosis

    Time frame: 11 years

    Liver fibrosis status

  165. INR: international normalized ratio

    Time frame: 11 years

    Standard liver evaluation

  166. prothrombin+proconvertin (PP)

    Time frame: 11 years

    Standard liver evaluation

  167. ALAT: alanine transaminase

    Time frame: 11 years

    Standard liver evaluation

  168. ASAT: Aspartate transaminase

    Time frame: 11 years

    Standard liver evaluation

  169. GGT: Gamma-glutamyl transferase

    Time frame: 11 years

    Standard liver evaluation

  170. Bilirubin

    Time frame: 11 years

    Standard liver evaluation

  171. Alkaline phosphatase

    Time frame: 11 years

    Standard liver evaluation

  172. Ammonia

    Time frame: 11 years

    Standard liver evaluation

  173. Thrombocytes

    Time frame: 11 years

    Standard liver evaluation

  174. Ultrasound of liver and bile ducts with elastography

    Time frame: 16 years

    % of patients with liver fibrosis measured with ultrasound

  175. Liver biopsy

    Time frame: 16 years

    Level of liver fibrosis (grade 0-4)

  176. FGF-19: Fibroblast growth factor 19

    Time frame: 16 years

    Liver fibrosis status

  177. ELF-score: Enhanced Liver Fibrosis

    Time frame: 16 years

    Liver fibrosis status

  178. INR: international normalized ratio

    Time frame: 16 years

    Standard liver evaluation

  179. prothrombin+proconvertin (PP)

    Time frame: 16 years

    Standard liver evaluation

  180. ALAT: alanine transaminase

    Time frame: 16 years

    Standard liver evaluation

  181. ASAT: Aspartate transaminase

    Time frame: 16 years

    Standard liver evaluation

  182. GGT: Gamma-glutamyl transferase

    Time frame: 16 years

    Standard liver evaluation

  183. Bilirubin

    Time frame: 16 years

    Standard liver evaluation

  184. Alkaline phosphatase

    Time frame: 16 years

    Standard liver evaluation

  185. Ammonia

    Time frame: 16 years

    Standard liver evaluation

  186. Thrombocytes

    Time frame: 16 years

    Standard liver evaluation

  187. Clinical examination: Cirrhosis stigmata

    Time frame: Inclusion

    Incidence of spider angioma

  188. Clinical examination: Cirrhosis stigmata

    Time frame: 1 year

    Incidence of spider angioma

  189. Clinical examination: Cirrhosis stigmata

    Time frame: 2 years

    Incidence of spider angioma

  190. Clinical examination: Cirrhosis stigmata

    Time frame: 6 years

    Incidence of spider angioma

  191. Clinical examination: Cirrhosis stigmata

    Time frame: 11 years

    Incidence of spider angioma

  192. Clinical examination: Cirrhosis stigmata

    Time frame: 16 years

    Incidence of spider angioma

  193. Clinical examination: Cirrhosis stigmata

    Time frame: Inclusion

    Incidence of ascitis

  194. Clinical examination: Cirrhosis stigmata

    Time frame: 1 year

    Incidence of ascitis

  195. Clinical examination: Cirrhosis stigmata

    Time frame: 2 years

    Incidence of ascitis

  196. Clinical examination: Cirrhosis stigmata

    Time frame: 6 years

    Incidence of ascitis

  197. Clinical examination: Cirrhosis stigmata

    Time frame: 11 years

    Incidence of ascitis

  198. Clinical examination: Cirrhosis stigmata

    Time frame: 16 years

    Incidence of ascitis

  199. Clinical examination: Cirrhosis stigmata

    Time frame: Inclusion

    Incidence of palmar erythema

  200. Clinical examination: Cirrhosis stigmata

    Time frame: 1 year

    Incidence of palmar erythema

  201. Clinical examination: Cirrhosis stigmata

    Time frame: 2 years

    Incidence of palmar erythema

  202. Clinical examination: Cirrhosis stigmata

    Time frame: 6 years

    Incidence of palmar erythema

  203. Clinical examination: Cirrhosis stigmata

    Time frame: 11 years

    Incidence of palmar erythema

  204. Clinical examination: Cirrhosis stigmata

    Time frame: 16 years

    Incidence of palmar erythema

  205. Anthropometry: Length

    Time frame: Inclusion

    cm

  206. Anthropometry: Length

    Time frame: 1 year

    cm

  207. Anthropometry: Length

    Time frame: 2 years

    cm

  208. Anthropometry: Height

    Time frame: 6 years

    cm

  209. Anthropometry: Height

    Time frame: 11 years

    cm

  210. Anthropometry: Height

    Time frame: 16 years

    cm

  211. Anthropometry: Weight

    Time frame: Inclusion

    kg

  212. Anthropometry: Weight

    Time frame: 1 year

    kg

  213. Anthropometry: Weight

    Time frame: 2 years

    kg

  214. Anthropometry: Weight

    Time frame: 6 years

    kg

  215. Anthropometry: Weight

    Time frame: 11 years

    kg

  216. Anthropometry: Weight

    Time frame: 16 years

    kg

  217. Anthropometry: Mid-upper arm circumference (MUAC)

    Time frame: Inclusion

    mm

  218. Anthropometry: Mid-upper arm circumference (MUAC)

    Time frame: 1 year

    mm

  219. Anthropometry: Mid-upper arm circumference (MUAC)

    Time frame: 2 years

    mm

  220. Anthropometry: Mid-upper arm circumference (MUAC)

    Time frame: 6 years

    mm

  221. Anthropometry: Mid-upper arm circumference (MUAC)

    Time frame: 11 years

    mm

  222. Anthropometry: Mid-upper arm circumference (MUAC)

    Time frame: 16 years

    mm

  223. Anthropometry: Head circumference

    Time frame: Inclusion

    cm

  224. Anthropometry: Head circumference

    Time frame: 1 year

    cm

  225. Anthropometry: Head circumference

    Time frame: 2 years

    cm

  226. Anthropometry: Head circumference

    Time frame: 6 years

    cm

  227. Anthropometry: Head circumference

    Time frame: 11 years

    cm

  228. Anthropometry: Head circumference

    Time frame: 16 years

    cm

  229. Essential fatty acids

    Time frame: Inclusion

  230. Essential fatty acids

    Time frame: 1 year

  231. Essential fatty acids

    Time frame: 2 years

  232. Essential fatty acids

    Time frame: 6 years

  233. Essential fatty acids

    Time frame: 11 years

  234. Essential fatty acids

    Time frame: 16 years

  235. IGF-1

    Time frame: Inclusion

    Insulin-like growth factor 1

  236. IGF-1

    Time frame: 1 year

    Insulin-like growth factor 1

  237. IGF-1

    Time frame: 2 years

    Insulin-like growth factor 1

  238. IGF-1

    Time frame: 6 years

    Insulin-like growth factor 1

  239. IGF-1

    Time frame: 11 years

    Insulin-like growth factor 1

  240. IGF-1

    Time frame: 16 years

    Insulin-like growth factor 1

  241. Meal stimulation measuring incretin

    Time frame: Inclusion

  242. Meal stimulation measuring incretin

    Time frame: 1 year

  243. Meal stimulation measuring incretin

    Time frame: 2 years

  244. Meal stimulation measuring incretin

    Time frame: 6 years

  245. Meal stimulation measuring incretin

    Time frame: 11 years

  246. Meal stimulation measuring incretin

    Time frame: 16 years

  247. Bile acid

    Time frame: Inclusion

  248. Bile acid

    Time frame: 1 year

  249. Bile acid

    Time frame: 2 years

  250. Bile acid

    Time frame: 6 years

  251. Bile acid

    Time frame: 11 years

  252. Bile acid

    Time frame: 16 years

  253. Autotaxin

    Time frame: Inclusion

  254. Autotaxin

    Time frame: 1 year

  255. Autotaxin

    Time frame: 2 years

  256. Autotaxin

    Time frame: 6 years

  257. Autotaxin

    Time frame: 11 years

  258. Autotaxin

    Time frame: 16 years

  259. EDTA clearance

    Time frame: Inclusion

    Glomerular Filtration Rate Measured by 51 Cr-EDTA Clearance

  260. EDTA clearance

    Time frame: 1 year

    Glomerular Filtration Rate Measured by 51 Cr-EDTA Clearance

  261. EDTA clearance

    Time frame: 2 years

    Glomerular Filtration Rate Measured by 51 Cr-EDTA Clearance

  262. EDTA clearance

    Time frame: 6 years

    Glomerular Filtration Rate Measured by 51 Cr-EDTA Clearance

  263. EDTA clearance

    Time frame: 11 years

    Glomerular Filtration Rate Measured by 51 Cr-EDTA Clearance

  264. EDTA clearance

    Time frame: 16 years

    Glomerular Filtration Rate Measured by 51 Cr-EDTA Clearance

  265. Vaccination status

    Time frame: Inclusion

    Level of antibodies

  266. Vaccination status

    Time frame: 1 year

    Level of antibodies

  267. Vaccination status

    Time frame: 2 years

    Level of antibodies

  268. Vaccination status

    Time frame: 6 years

    Level of antibodies

  269. Vaccination status

    Time frame: 11 years

    Level of antibodies

  270. Vaccination status

    Time frame: 16 years

    Level of antibodies

  271. Immunoresponse: RTE

    Time frame: Inclusion

    Recent thymic emigrants

  272. Immunoresponse: RTE

    Time frame: 1 year

    Recent thymic emigrants

  273. Immunoresponse: RTE

    Time frame: 2 years

    Recent thymic emigrants

  274. Immunoresponse: RTE

    Time frame: 6 years

    Recent thymic emigrants

  275. Immunoresponse: RTE

    Time frame: 11 years

    Recent thymic emigrants

  276. Immunoresponse: RTE

    Time frame: 16 years

    Recent thymic emigrants

  277. Immunoresponse: Flow panel

    Time frame: Inclusion

    T-cell differentiation

  278. Immunoresponse: Flow panel

    Time frame: 1 year

    T-cell differentiation

  279. Immunoresponse: Flow panel

    Time frame: 2 years

    T-cell differentiation

  280. Immunoresponse: Flow panel

    Time frame: 6 years

    T-cell differentiation

  281. Immunoresponse: Flow panel

    Time frame: 11 years

    T-cell differentiation

  282. Immunoresponse: Flow panel

    Time frame: 16 years

    T-cell differentiation

  283. Immunoresponse: Immunoglobulin

    Time frame: Inclusion

  284. Immunoresponse: Immunoglobulin

    Time frame: 1 year

  285. Immunoresponse: Immunoglobulin

    Time frame: 2 years

  286. Immunoresponse: Immunoglobulin

    Time frame: 6 years

  287. Immunoresponse: Immunoglobulin

    Time frame: 11 years

  288. Immunoresponse: Immunoglobulin

    Time frame: 16 years

  289. Immunoresponse: Somatic hyper mutation

    Time frame: Inclusion

  290. Immunoresponse: Somatic hyper mutation

    Time frame: 1 year

  291. Immunoresponse: Somatic hyper mutation

    Time frame: 2 years

  292. Immunoresponse: Somatic hyper mutation

    Time frame: 6 years

  293. Immunoresponse: Somatic hyper mutation

    Time frame: 11 years

  294. Immunoresponse: Somatic hyper mutation

    Time frame: 16 years

  295. Epstein-Barr Virus (EBV)

    Time frame: Inclusion

    level of EBV DNA present

  296. Epstein-Barr Virus (EBV)

    Time frame: 1 year

    level of EBV DNA present

  297. Epstein-Barr Virus (EBV)

    Time frame: 2 years

    level of EBV DNA present

  298. Epstein-Barr Virus (EBV)

    Time frame: 6 years

    level of EBV DNA present

  299. Epstein-Barr Virus (EBV)

    Time frame: 11 years

    level of EBV DNA present

  300. Epstein-Barr Virus (EBV)

    Time frame: 16 years

    level of EBV DNA present

  301. Cytomegalovirus (CMV)

    Time frame: Inclusion

    level of CMV DNA present

  302. Cytomegalovirus (CMV)

    Time frame: 1 year

    level of CMV DNA present

  303. Cytomegalovirus (CMV)

    Time frame: 2 years

    level of CMV DNA present

  304. Cytomegalovirus (CMV)

    Time frame: 6 years

    level of CMV DNA present

  305. Cytomegalovirus (CMV)

    Time frame: 11 years

    level of CMV DNA present

  306. Cytomegalovirus (CMV)

    Time frame: 16 years

    level of CMV DNA present

  307. Hepatobiliary scintigraphy

    Time frame: Inclusion

    Hepatic extraction fraction

  308. Hepatobiliary scintigraphy

    Time frame: 1 year

    Hepatic extraction fraction

  309. Hepatobiliary scintigraphy

    Time frame: 2 years

    Hepatic extraction fraction

  310. Hepatobiliary scintigraphy

    Time frame: 6 years

    Hepatic extraction fraction

  311. Hepatobiliary scintigraphy

    Time frame: 11 years

    Hepatic extraction fraction

  312. Hepatobiliary scintigraphy

    Time frame: 16 years

    Hepatic extraction fraction

  313. MRI of liver and bile ducts with elastography

    Time frame: Inclusion

    Liver stiffness

  314. MRI of liver and bile ducts with elastography

    Time frame: 1 year

    Liver stiffness

  315. MRI of liver and bile ducts with elastography

    Time frame: 2 years

    Liver stiffness

  316. MRI of liver and bile ducts with elastography

    Time frame: 6 years

    Liver stiffness

  317. MRI of liver and bile ducts with elastography

    Time frame: 11 years

    Liver stiffness

  318. MRI of liver and bile ducts with elastography

    Time frame: 16 years

    Liver stiffness

  319. Fibroscan

    Time frame: Inclusion

    Liver stiffness (number)

  320. Fibroscan

    Time frame: 1 year

    Liver stiffness (number)

  321. Fibroscan

    Time frame: 2 years

    Liver stiffness (number)

  322. Fibroscan

    Time frame: 6 years

    Liver stiffness (number)

  323. Fibroscan

    Time frame: 11 years

    Liver stiffness (number)

  324. Fibroscan

    Time frame: 16 years

    Liver stiffness (number)

  325. Indocyanine green clearance

    Time frame: Inclusion

  326. Indocyanine green clearance

    Time frame: 1 year

  327. Indocyanine green clearance

    Time frame: 2 years

  328. Indocyanine green clearance

    Time frame: 6 years

  329. Indocyanine green clearance

    Time frame: 11 years

  330. Indocyanine green clearance

    Time frame: 16 years

  331. Fecal fat measurements

    Time frame: Inclusion

  332. Fecal fat measurements

    Time frame: 1 year

  333. Fecal fat measurements

    Time frame: 2 years

  334. Fecal fat measurements

    Time frame: 6 years

  335. Fecal fat measurements

    Time frame: 11 years

  336. Fecal fat measurements

    Time frame: 16 years

  337. Thymus scan with ultrasound

    Time frame: Inclusion

    Thymic index (measurement of size)

  338. Thymus scan with ultrasound

    Time frame: 1 year

    Thymic index (measurement of size)

  339. Thymus scan with ultrasound

    Time frame: 2 years

    Thymic index (measurement of size)

  340. Thymus scan with ultrasound

    Time frame: 6 years

    Thymic index (measurement of size)

  341. Thymus scan with ultrasound

    Time frame: 11 years

    Thymic index (measurement of size)

  342. Thymus scan with ultrasound

    Time frame: 16 years

    Thymic index (measurement of size)

  343. DEXA scan

    Time frame: Inclusion

    Dual energy x-ray absorptiometry

  344. DEXA scan

    Time frame: 1 year

    Dual energy x-ray absorptiometry

  345. DEXA scan

    Time frame: 2 years

    Dual energy x-ray absorptiometry

  346. DEXA scan

    Time frame: 6 years

    Dual energy x-ray absorptiometry

  347. DEXA scan

    Time frame: 11 years

    Dual energy x-ray absorptiometry

  348. DEXA scan

    Time frame: 16 years

    Dual energy x-ray absorptiometry

  349. PEDS-QL

    Time frame: Inclusion

    Pediatric Quality of Life Inventory Higher scores indicate better quality of life, from 0-100

  350. PEDS-QL

    Time frame: 1 year

    Pediatric Quality of Life Inventory Higher scores indicate better quality of life, from 0-100

  351. PEDS-QL

    Time frame: 2 years

    Pediatric Quality of Life Inventory Higher scores indicate better quality of life, from 0-100

  352. PEDS-QL

    Time frame: 6 years

    Pediatric Quality of Life Inventory Higher scores indicate better quality of life, from 0-100

  353. PEDS-QL

    Time frame: 11 years

    Pediatric Quality of Life Inventory Higher scores indicate better quality of life, from 0-100

  354. PEDS-QL

    Time frame: 16 years

    Pediatric Quality of Life Inventory Higher scores indicate better quality of life, from 0-100

  355. Leptin

    Time frame: Inclusion

  356. Leptin

    Time frame: 1 year

  357. Leptin

    Time frame: 2 years

  358. Leptin

    Time frame: 6 years

  359. Leptin

    Time frame: 11 years

  360. Leptin

    Time frame: 16 years

Study contacts

Contact information is provided by the study sponsor or research team.

Vibeke Brix Christensen, MD, PhD, DMSc

CONTACT

[email protected]

+4535458842

Sponsors and collaborators

Lead sponsor

Rigshospitalet, Denmark

Other

Registry information

Official study title

BILACO Trial: Biliary Atresia - a Severe Complex Congenital Liver Disease With High Mortality, Compromised Neurological Development, Severe Malnutrition and Unknown Etiology

Acronym: BILACO

Important dates

Study start
2020
Primary completion
2039
Study completion
2040
First posted
Jun 1, 2022
Registry last updated
Jun 1, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.